What is the definition of Acute Interstitial Pneumonia?

Acute interstitial pneumonia (AIP) is a rare and serious condition that affects the lungs. The signs and symptoms generally develop and progress rapidly. In the early stages of the condition, affected people may experience upper respiratory and/or viral-like symptoms such as cough, shortness of breath, and fever. This is followed by the rapid onset of respiratory failure and the need for mechanical ventilation in the majority of cases. The underlying cause of AIP is unknown. Most cases occur sporadically in people with no family history of the condition. There is, unfortunately, no proven treatment for AIP. Supportive care is generally recommended to address the signs and symptoms of the condition. Glucocorticoid therapy and other immunosuppressive therapies are often used; however, the benefits of these treatments remain unclear.

What are the alternative names for Acute Interstitial Pneumonia?

  • Acute interstitial pneumonitis
  • Hamman-Rich syndrome
  • Condition: Rapidly Progressive Interstitial Lung Disease in Pregnant Patient with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis
  • Journal: Frontiers in immunology
  • Treatment Used: Combined Immunosuppressant Regimen
  • Number of Patients: 1
  • Published —
This case report describes a pregnant woman with clinically amyopathic dermatomyositis with positive anti-melanoma differentiation-associated gene 5 antibody treated with combined immunosuppressive therapy.
  • Condition: Acute Exacerbation of Idiopathic Pulmonary Fibrosis (IPF)
  • Journal: Scientific reports
  • Treatment Used: Corticosteroids
  • Number of Patients: 63
  • Published —
This study examined the risk factors for recurrent acute exacerbations (worsening; AEs) in patients with idiopathic pulmonary fibrosis (IPF).
Clinical Trial
  • Status: Not yet recruiting
  • Intervention Type: Other, Device
  • Participants: 80
  • Start Date: January 2022
Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
Clinical Trial
  • Status: Not yet recruiting
  • Phase: N/A
  • Intervention Type: Biological
  • Participants: 40
  • Start Date: September 1, 2021
Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interstitial Lung Disease